Departamento de Biología Celular y Desarrollo, Instituto de Fisiología Celular, UNAM, Circuito Exterior s/n Ciudad Universitaria, Coyoacán 04510, Cd.Mx., México.
Departamento de Genética Molecular, Instituto de Fisiología Celular, UNAM, Circuito Exterior s/n Ciudad Universitaria, Coyoacán 04510, Cd.Mx., México.
J Cell Biochem. 2018 Jan;119(1):401-413. doi: 10.1002/jcb.26192. Epub 2017 Jul 4.
The pathological characteristic of cirrhosis is scarring which results in a structurally distorted and dysfunctional liver. Previously, we demonstrated that Col1a1 and Pparg genes are deregulated in CCl -induced cirrhosis but their normal expression levels are recovered upon treatment with IFC-305, an adenosine derivative. We observed that adenosine was able to modulate S-adenosylmethionine-dependent trans-methylation reactions, and recently, we found that IFC-305 modulates HDAC3 expression. Here, we investigated whether epigenetic mechanisms, involving DNA methylation processes and histone acetylation, could explain the re-establishment of gene expression mediated by IFC-305 in cirrhosis. Therefore, Wistar rats were CCl treated and a sub-group received IFC-305 to reverse fibrosis. Global changes in DNA methylation, 5-hydroxymethylation, and histone H4 acetylation were observed after treatment with IFC-305. In particular, during cirrhosis, the Pparg gene promoter is depleted of histone H4 acetylation, whereas IFC-305 administration restores normal histone acetylation levels which correlates with an increase of Pparg transcript and protein levels. In contrast, the promoter of Col1a1 gene is hypomethylated during cirrhosis but gains DNA methylation upon treatment with IFC-305 which correlates with a reduction of Col1a1 transcript and protein levels. Our results suggest a model in which cirrhosis results in a general loss of permissive chromatin histone marks which triggers the repression of the Pparg gene and the upregulation of the Col1a1 gene. Treatment with IFC-305 restores epigenetic modifications globally and specifically at the promoters of Pparg and Col1a1 genes. These results reveal one of the mechanisms of action of IFC-305 and suggest a possible therapeutic function in cirrhosis. J. Cell. Biochem. 119: 401-413, 2018. © 2017 Wiley Periodicals, Inc.
肝硬化的病理特征是瘢痕形成,导致肝脏结构扭曲和功能障碍。以前,我们证明 Col1a1 和 Pparg 基因在 CCl 诱导的肝硬化中失调,但在用腺苷衍生物 IFC-305 治疗后其正常表达水平得到恢复。我们观察到腺苷能够调节 S-腺苷甲硫氨酸依赖性转甲基反应,最近我们发现 IFC-305 调节 HDAC3 表达。在这里,我们研究了表观遗传机制,包括 DNA 甲基化过程和组蛋白乙酰化,是否可以解释 IFC-305 在肝硬化中重新建立基因表达的机制。因此,我们用 CCl 处理 Wistar 大鼠,并对亚组进行 IFC-305 治疗以逆转纤维化。用 IFC-305 处理后观察到 DNA 甲基化、5-羟甲基化和组蛋白 H4 乙酰化的全局变化。特别是,在肝硬化期间,Pparg 基因启动子耗尽组蛋白 H4 乙酰化,而 IFC-305 给药恢复正常的组蛋白乙酰化水平,这与 Pparg 转录物和蛋白质水平的增加相关。相比之下,Col1a1 基因的启动子在肝硬化期间低甲基化,但在用 IFC-305 处理时获得 DNA 甲基化,这与 Col1a1 转录物和蛋白质水平的降低相关。我们的结果表明,肝硬化导致一般的组蛋白染色质标记缺失,从而触发 Pparg 基因的抑制和 Col1a1 基因的上调。用 IFC-305 治疗可全局恢复表观遗传修饰,并特异性地恢复 Pparg 和 Col1a1 基因启动子的修饰。这些结果揭示了 IFC-305 的作用机制之一,并提示其在肝硬化中的可能治疗功能。J. Cell. Biochem. 119: 401-413, 2018. © 2017 Wiley Periodicals, Inc.